FDA Advisory Panel Votes 9–0 to Approve Moderna's mRNA Flu Vaccine mFlusiva
In a landmark unanimous decision, the Food and Drug Administration's independent advisory committee voted 9–0 in support of approving Moderna's seasonal mRNA flu vaccine, commercially branded as mFlusiva and clinically known as mRNA-1010. The vote marks a pivotal moment in the evolution of flu prevention, applying the same messenger RNA technology that powered the COVID-19 vaccine revolution to one of the world's most persistent seasonal threats. The decision came after an all-day meeting of the FDA's Vaccines and Related Biological Products Advisory Committee, better known as VRBPAC, and follows a period of internal agency drama that briefly threatened to delay the review process altogether.
What Is mFlusiva and How Does It Work?
mFlusiva is Moderna's seasonal influenza vaccine built on mRNA technology — the same platform used in the company's highly successful COVID-19 vaccines. Instead of using weakened or inactivated flu virus proteins as traditional vaccines do, mRNA vaccines deliver genetic instructions that teach the body's cells to produce flu-related antigens on their own. This triggers a robust immune response without ever introducing live virus into the body.
The mRNA approach offers several key advantages over conventional vaccine manufacturing. It allows for significantly faster production timelines, meaning vaccine formulations can potentially be updated more quickly each season to match circulating flu strains. This adaptability is one of the primary reasons researchers and public health experts have been excited about applying mRNA technology to influenza for years.
The Clinical Trial Data Behind the Vote
The unanimous vote from VRBPAC was backed by compelling clinical evidence drawn from two separate Phase 3 trials, both of which painted an encouraging picture of mFlusiva's performance and safety profile.
Phase 3 Trial in Adults Age 50 and Older
The larger of the two trials enrolled more than 40,000 adults aged 50 years and older. This study found that mFlusiva was approximately 27 percent more effective against seasonal flu compared to a standard-dose flu shot. That is a clinically meaningful improvement, particularly given that influenza causes hundreds of thousands of hospitalizations and tens of thousands of deaths in the United States each year. For adults in this age group, who face elevated risks from flu complications, even a moderate boost in vaccine efficacy can translate into significant real-world health benefits.
Phase 3 Trial in Adults Age 65 and Older
A second, smaller Phase 3 trial focused specifically on adults aged 65 and older — a demographic that typically receives high-dose flu vaccines due to their naturally weaker immune responses. This trial included data from nearly 3,000 participants and showed that mFlusiva produces stronger immune responses than the high-dose flu vaccine already recommended for this age group. That result is particularly significant because high-dose flu vaccines are themselves considered more effective than standard flu shots in older adults, making mFlusiva's performance against that benchmark all the more impressive.
Safety Profile
Beyond efficacy, FDA scientists who presented at the VRBPAC meeting noted that the safety profile of mFlusiva was generally favorable. While mRNA vaccines can produce temporary side effects such as injection-site soreness, fatigue, and low-grade fever — side effects consistent with a strong immune response — no serious safety signals emerged in the trial data that gave the committee cause for concern. The FDA's own scientific review was supportive of the vaccine, adding further institutional weight to the panel's ultimate recommendation.
The Agency Drama Behind the Scenes
The path to Friday's vote was not without turbulence. A Trump appointee at the FDA had initially attempted to block mFlusiva from even being placed on the VRBPAC review agenda — an unusual move that drew scrutiny from health policy observers and vaccine advocates. The effort to sideline the advisory review raised concerns about the intersection of politics and the traditionally science-driven FDA approval process.
Despite that friction, the review proceeded, and the committee's unanimous 9–0 vote sent a clear signal that the scientific case for mFlusiva stood on solid footing. The episode also reignited broader conversations about the importance of preserving the independence of FDA advisory panels from political interference, particularly when lives are on the line.
Why This Vote Matters for Public Health
Influenza remains a serious public health burden globally. In the United States alone, the CDC estimates that flu results in millions of illnesses, hundreds of thousands of hospitalizations, and thousands to tens of thousands of deaths each season. Vaccine uptake, while improving, still falls short of ideal coverage — and one driver of hesitancy is the perception that flu shots are only modestly effective.
A vaccine that demonstrably outperforms existing options, backed by a large-scale clinical trial, could meaningfully shift that dynamic. If mFlusiva clears final FDA approval following the VRBPAC recommendation, it would represent the first mRNA seasonal flu vaccine to reach the U.S. market — a historic milestone in immunization history.
What Comes Next
A positive VRBPAC vote is a strong indicator but not a final FDA approval. The agency will now review the committee's recommendation alongside all available clinical, safety, and manufacturing data before issuing a formal ruling. If approved, mFlusiva's rollout would depend on production capacity, CDC advisory recommendations, and ultimately, healthcare provider and patient uptake.
For Moderna, the approval would mark a significant expansion of its mRNA vaccine portfolio beyond COVID-19 and validate the company's long-term bet that mRNA technology can be applied broadly across infectious disease prevention.
The Bottom Line
The FDA advisory committee's 9–0 vote in favor of Moderna's mFlusiva is a watershed moment for both mRNA vaccine technology and seasonal flu prevention. With strong efficacy data — including a 27 percent improvement over standard flu shots in adults 50 and older — a favorable safety profile, and the backing of the FDA's own scientists, mFlusiva appears poised to become a powerful new tool in the public health arsenal against influenza. As the FDA deliberates its final decision, the unanimous advisory vote signals that the science is clear: mRNA flu vaccines are ready for their moment.